Suchergebnisse - "Curigliano, G"

PubPharm (138)

21

ESMO Expert Consensus Statements on Cancer Survivorship : promoting high-quality survivorship care and research in Europe

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Vaz-Luis, I. | Masiero, M. | Cavaletti, G. | +25

22

ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Paluch-Shimon, S. | Cardoso, F. | Partridge, A. | +20

23

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy : update from the ARROW trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Griesinger, F. | Curigliano, G. | Thomas, M. | +23

CommentIn: Nat Rev Clin Oncol. 2022 Oct;19(10):615. - PMID 35999290

24

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

enthalten in: ESMO open | 2022

von Kanesvaran, R. | Castro, E. | Wong, A. | +21

25

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer : a report from the ESMO Precision Medicine Working Group

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Pascual, J. | Attard, G. | Bidard, F. | +17

26

Risk-adapted modulation through de-intensification of cancer treatments : an ESMO classification

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Trapani, D. | Franzoi, M. | Burstein, H. | +14

CommentIn: Ann Oncol. 2022 Jul;33(7):672-673. - PMID 35568278

27

Quantifying geographical accessibility to cancer clinical trials in different income landscapes

enthalten in: ESMO open | 2022

von Tini, G. | Trapani, D. | Duso, B. | +4

28

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Passaro, A. | Leighl, N. | Blackhall, F. | +31

29

How I treat HER2-positive early breast cancer : how long adjuvant trastuzumab is needed?

enthalten in: ESMO open | 2022

von Morganti, S. | Bianchini, G. | Giordano, A. | +3

30

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB) : final overall survival analysis

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Curigliano, G. | Mueller, V. | Borges, V. | +17

ErratumIn: Ann Oncol. 2023 Jul;34(7):630. - PMID 36564285